<DOC>
	<DOCNO>NCT00005057</DOCNO>
	<brief_summary>RATIONALE : Inserting modify herpesvirus gene person 's melanoma cell may make cancer sensitive antiviral agent ganciclovir . PURPOSE : Phase I trial study effectiveness gene therapy treat patient stage IV melanoma .</brief_summary>
	<brief_title>Gene Therapy Ganciclovir Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ganciclovir administer IV every 12 hour 7 day combination adenovirus RSV-TK administer direct intralesional injection patient cutaneous subcutaneous metastatic malignant melanoma . II . Determine dose limit toxicity regimen patient population . III . Evaluate response ( local distant metastatic site ) , duration response , response ganciclovir dose , impact local treatment adenovirus RSV-TK ganciclovir `` suicide '' gene therapy may overall survival patient . OUTLINE : This dose escalation study ganciclovir . Patients stratify accord response index lesion metastatic disease site . Patients receive intratumoral injection adenovirus RSV-TK day 1 . Ganciclovir IV administer every 12 hour day 3-10 total 14 dos . Patients sustain partial response ( PR ) complete response ( CR ) may retreat 2 week document PR CR . Cohorts 3-6 patient receive escalate dos ganciclovir maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow 3 week , 4 week , 60 day , every 2 month 6 month , every 3 month 1.5 year . PROJECTED ACCRUAL : A maximum 27 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced stage IV malignant melanoma M1 All pathologic subtypes eligible Tridimensionally measurable disease At least 1 discreet easily accessible measurable cutaneous subcutaneous lesion volume great 3 cm3 physical examination use Vernier caliper Ulcerated necrotic lesion may serve index lesion Not candidate curative surgical resection Visceral metastasis , include brain lesion , eligible provide rapidly progressive CNS metastasis likely result death within 3 month PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,800/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : BUN great 1.5 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN Renal : Creatinine great 1.8 mg/dL OR Creatinine clearance least 70 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No clinically significant medical disease poorly control and/or expect impact patient survival would preclude study therapy No significant cognitive impairment No serious active infection require intravenous antibiotic antiviral therapy No clinical AIDS No primary immunodeficiency No concurrent active malignancy No history sensitivity ganciclovir antiviral drug family No prior severe reaction adenovirus herpes virus infection ( e.g. , toxic epidermal necrolysis StevensJohnson syndrome ) PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biological response modifier therapy ( e.g. , interleukin2 , interferon ) recover No prior gene therapy use adenoviral base vector , chimeric adenoviral base vector , HSVtk thymidine kinase base therapy No concurrent biological response modifier therapy No concurrent gene therapy include ribozyme antisense base therapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas , melphalan , mitomycin ) recover No concurrent antineoplastic chemotherapy Endocrine therapy : Concurrent replacement therapeutic corticosteroid allow Radiotherapy : Prior radiotherapy allow provided index lesion within radiation field Recovered prior radiotherapy No concurrent radiotherapy except CNS metastasis provide index lesion within radiation field Surgery : See Disease Characteristics Recovered prior surgery Other : No concurrent ganciclovir , acyclovir , similar antiviral drug No concurrent immunosuppressive therapy ( e.g. , organ allograft )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>lentigo maligna malignant melanoma</keyword>
	<keyword>superficial spread malignant melanoma</keyword>
	<keyword>acral lentiginous malignant melanoma</keyword>
	<keyword>nodular malignant melanoma</keyword>
</DOC>